Hemophilia A

All articles by Hemophilia A

BioMarin’s hemophilia A gene therapy chugs across FDA finish line
BioMarin’s hemophilia A gene therapy chugs across FDA finish line
Marc Iskowitz
June 30, 2023
1:04 pm

BioMarin’s one-time treatment is launching with a $2.9M price tag and a money-back guarantee, but the rollout may take longer than anticipated.

Two drugs in the pipeline representing unique marketing challenges
Two drugs in the pipeline representing unique marketing challenges
Sony Salzman
June 5, 2018
6:00 pm

Two touted products in the pipeline reflect three of medical marketing’s most profound modern-era challenges.

Five things for pharma marketers to know: Thursday, May 11, 2017
Five things for pharma marketers to know: Thursday, May 11, 2017
Virginia Lau
May 11, 2017
2:40 pm

FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs

Roche gears up to enter loaded hemophilia A drug market
Roche gears up to enter loaded hemophilia A drug market
Rebecca Mayer Knutsen
February 16, 2017
3:15 pm

A loaded hemophilia A drug market is an indication patients in and around it are well-served, but that hasn’t stopped contenders such as Roche’s emicizumab.

  • From Our Partners